The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Revolution Medicines Inc COM 76155X100 13,508 685,011 SH   SOLE   685,011 0 0
RAPT Therapeutics Inc COM 75382E109 38,482 1,599,417 SH   SOLE   1,599,417 0 0
NGM Biopharmaceuticals Inc COM 62921N105 16,990 1,298,908 SH   SOLE   1,298,908 0 0
Nurix Therapeutics Inc COM 67080M103 4,262 327,123 SH   SOLE   327,123 0 0